BarcelonaBarcelona, 30 March 2006.- Almirall announces the appointment of Dr. John Efthimiou as the new Global Medical Director for the R&D area. Dr Efthimiou’s international experience in the pharmaceutical sector and a number of key therapeutic areas will be a valuable addition to Almirall.
Dr Efthimiou was trained and practised as a physician in London and Oxford Teaching Hospitals, specialising in both Pulmonology and General Medicine and gained a Doctorate in Medicine and Fellowship of the Royal College of Physicians (UK). Previously he held very relevant positions in Glaxo SmithKline as Head of Respiratory Clinical Development, in Chugai Pharma Europe as Director of R&D and with Novartis as Global Head of Exploratory Clinical Development Profiling.
Almirall, a leading company committed to health
Almirall is a consolidated international pharmaceutical company that researches, develops and commercialises its own R&D and licensed specialities with the aim of improving health and quality of life.The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (chronic obstructive pulmonary disease), psoriasis and rheumatoid arthritis.
Almirall, whose Headquarters are in Barcelona (Spain), has a staff of 3,200 people, 500 of whom form part of the R&D team. It is currently present in approximately 100 countries with its own products and licensed products from other prestigious companies.The company is strengthening its direct presence in Europe and Latin America via affiliates.
